Target Discovery Inc. is ushering in a new era of accurate and affordable chemical testing characterized by simplicity and certainty – regardless of the application.


Target Discovery Inc (TDI) is focused on delivering the next-generation of chemical tests for applications across clinical diagnostics, personalized medicine, forensics, environmental, and food & beverage analysis.

Our team of world-class scientists is pioneering innovative testing strategies based on leading-edge instrumental analysis, machine learning approaches, and comprehensive, carefully curated databases.

Our approach draws on advances across disciplines including analytical chemistry (mass spectrometry, microfluidic), surface chemistry, cloud-computing, machine learning and high throughput automation. Our unique approach speeds test development time, lowers test cost, and delivers easily-interpretable results.

Target Discovery’s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative analytical strategies to all who would benefit. We are committed to helping our customers reduce their risk and expedite delivery of safer, better products and services.

Our powerful platform and predictive analytic capabilities, allow you to extract much more relevant information from your samples. We give you faster processes, deeper insights, and actionable evidence.


Target Discovery was founded to improve the way chemical testing is performed. We are driven by a vision to liberate analysis from the hands of highly trained staff, dependence on costly equipment, complex methods, and unmanageably complicated interpretation and reporting.

Target Discovery is ushering in a new era of accurate and affordable chemical testing marked by simplicity and certainty – regardless of the specific application. Whether it is the complexities of posttranslational modifications of proteins in human tissue and fluids or the challenges of detecting contaminants in food products, manufacturing processes, supply chains and/or packaging, we are actively developing tools to address the issue.

TDI software uses machine learning and multivariate statistical models to train, define, query and advise. We don’t confuse you with chemical mumbo-jumbo. Instead, within minutes of testing we provide you with a simple, accurate and meaningful answer tailored to your specific question.

At the heart of it all is TDI’s uniquely powerful and sensitive analyzer, optimized sample handling methods and a software platform that utilizes the raw data to performs sample recognition, verify sample authenticity and identify adulteration/impurities.



Target Discovery generates detailed molecular fingerprints from complex biological samples and then converts the avalanche of associated data into a simple output anyone can understand. We are committed to improving the speed, cost and simplify of chemical analysis, while at the same time, increasing the meaningfulness of the information extracted from each analysis.


We see a world where everyone has greater access to information about themselves and the world they live in.


 Jeffrey N. Peterson, CEO, co-founded Target Discovery, Inc. and its subsidiary, Veritomyx, Inc., where he leads as Chairman & CEO. Mr. Peterson also serves as Chairman of Pressure Biosciences, Inc. (PBIO) and of Imaging3 (IGNG). His broad executive leadership experience included a career in Abbott Laboratories, as CEO & GM of Abbott South Africa, and in pivotal roles in Abbott Diagnostics. He was previously CEO of SPO&A international business development consulting, and had a career rising through General Electric’s Engineered Materials and Plastics businesses. Mr. Peterson holds BSChemE and MSChemE degrees from MIT, and he has coauthored six issued patents and multiple scientific articles. Mr. Peterson serves on the Advisory Board for the California Technology Council and served 12 years on the Board of BayBio (CA Life Sciences Association). Mr. Peterson has been an active leader in the Coalition for 21st Century Medicine and in BIO’s Personalized Medicine & Diagnostics Group. He is Chair Emeritus of the BayBio Institute, served on the University of Texas MD Anderson Cancer Center’s Board of Advisors for the Center for Professional Development and Entrepreneurship, and continues to advise rising entrepreneurs.

 Mark W. Duncan, Ph.D., Director of Application Development & Scientific Affairs, has extensive experience in mass spectrometry, clinical diagnostics and analytical chemistry. Dr. Duncan was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia and thereafter, a Fogerty Fellow, National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA and Saudi Arabia and has established and directed proteomics/MS centers at three international institutions. He has also held senior appointments in industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.

 Adam L. Tenderholt, Ph.D., Director of Technology and Veritomyx Program, contributes substantial multidisciplinary scientific and computational experience to Target Discovery, Inc. Dr. Tenderholt holds a Ph.D. in Physical Chemistry (Stanford University) and dual B.A. degrees in Chemistry and Integrated Science (Northwestern University). He was also a postdoctoral scholar at the University of Washington where he studied proton-coupled electron transfer mechanisms using a variety of experimental and computational approaches. As a graduate student, he developed software for the processing and analysis of both experimental data (PySpline) and quantum chemical calculations (cclib and QMForge) and was responsible for the design and maintenance of the high-performance computational cluster in the laboratory of his advisor. Dr. Tenderholt has coauthored numerous publications in high-profile peer-reviewed journals. His Journal of Computational Chemistry publication describing the cclib platform for package‐independent computational chemistry algorithms has been cited over 2,000 times. Dr. Tenderholt is a member of the American Chemical Society and the American Society for Mass Spectrometry.

Visit TDI subsidiary Veritomyx, Inc., by clicking here.